Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|75|15|1747-1759

ISSN： 0270-4137

Source： THE PROSTATE, Vol.75, Iss.15, 2015-11, pp. : 1747-1759

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1747-1759

John Wiley & Sons Inc

Access to resources Recommend Favorite

Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments

By  

Current Signal Transduction Therapy, Vol. 4, Iss. 2, 2009-05 ,pp. : 130-143

Bentham Science Publishers

Access to resources Recommend Favorite

Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer

By  

BJU INTERNATIONAL, Vol. 121, Iss. 2, 2018-02 ,pp. : 203-208

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy

By                

International Journal of Molecular Medicine, Vol. 31, Iss. 6, 2013-01 ,pp. : 1449-1456

Spandidos Publications

Access to resources Recommend Favorite

GOLM1 promotes prostate cancer progression through activating PI3K‐AKT‐mTOR signaling

By  

THE PROSTATE, Vol. 78, Iss. 3, 2018-02 ,pp. : 166-177

John Wiley & Sons Inc

Access to resources Recommend Favorite